Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial

MLA

James N. Ingle, et al. “Abstract S3-08: Randomized Comparison of Adjuvant Tamoxifen (T) plus Ovarian Function Suppression (OFS) versus Tamoxifen in Premenopausal Women with Hormone Receptor-Positive (HR+) Early Breast Cancer (BC): Analysis of the SOFT Trial.” Cancer Research, vol. 75, May 2015, pp. S3-08. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs14-s3-08.

APA

James N. Ingle, Charles E. Geyer, Herve R Bonnefoi, Meritxell Bellet, Babara A Walley, HJ Burstein, Miguel Angel Climent, Stefan Buchholz, Gini F. Fleming, Silvana Martino, Manuela Rabaglio-Poretti, István Láng, Robert E. Coleman, Meredith M. Regan, Pierre Kerbrat, E.M. Ciruelos, Marco Colleoni, Lorenzo Pavesi, PA Francis, & Nancy E Davidson. (2015). Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial. Cancer Research, 75, S3-08. https://doi.org/10.1158/1538-7445.sabcs14-s3-08

Chicago

James N. Ingle, Charles E. Geyer, Herve R Bonnefoi, Meritxell Bellet, Babara A Walley, HJ Burstein, Miguel Angel Climent, et al. 2015. “Abstract S3-08: Randomized Comparison of Adjuvant Tamoxifen (T) plus Ovarian Function Suppression (OFS) versus Tamoxifen in Premenopausal Women with Hormone Receptor-Positive (HR+) Early Breast Cancer (BC): Analysis of the SOFT Trial.” Cancer Research 75 (May): S3-08. doi:10.1158/1538-7445.sabcs14-s3-08.